Technology
Health
Pharmaceutical

Hutchison China Meditech

$26.86
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.12 (0.45%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell HCM and other stocks, options, ETFs, and crypto commission-free!

About

Hutchison China MediTech Limited American Depositary Shares, also called Hutchison China Meditech, is a holding company, which engages in the research and development, manufactures, and sells pharmaceuticals and health oriented consumer products. It operates through the Innovation Platform and Commercial Platform segments. Read More The Innovation Platform segment relates to research and development of innovative therapeutics in oncology and autoimmune diseases. The Commercial Platform segment relates to prescription drugs which develops, manufacture, markets, and sale of prescription pharmaceuticals; and consumer health which comprised of development, manufacture, distribution, and marketing of over-the-counter pharmaceuticals, and consumer health products. The company was founded in June 2000 and is headquartered in Hong Kong.

Employees
714
Headquarters
Hong Kong, Central & Western
Founded
2000
Market Cap
3.56B
Price-Earnings Ratio
Dividend Yield
Average Volume
222.60K
High Today
$27.53
Low Today
$26.63
Open Price
$26.67
Volume
55.35K
52 Week High
$39.68
52 Week Low
$20.83

Collections

Technology
Health
Pharmaceutical
Research And Development
Consumer Products
Therapy
Advertising and Marketing
Retail

News

Yahoo FinanceApr 26

Did Hedge Funds Drop The Ball On Hutchison China MediTech Limited (HCM) ?

"Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of a value discipline will be in avoiding the biggest capital-destroying rocks. If a rock emerges on the crowded shore of U.S. momentum, it could result in a major liquidity challenge, as mo...

24
Seeking AlphaApr 21

Week In Review: Chi-Med Plans $500 Million Hong Kong IPO

CASI, a US in-licensing pharma with operations in China, acquired global rights to an investigational anti-CD38 immunotherapy from Black Belt Therapeutics of the UK. Hutchison China MediTech (Chi-Med) filed to IPO on the Hong Kong Exchange, following listings in London and on NASDAQ, where it has a market capitalization of over $4 billion. Deals and Financings Hutchison China MediTech (Chi-Med) [AIM:HCM] (NASDAQ:HCM) filed to IPO on the Hong Kong Exchange, following listings in London and on NASDAQ, wher...

11

Earnings

Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.